insights_auto
Why is MOLBIO down 3.12%?
Dive Deeperchevron_right
MOLBIO:NSE
Molbio Diagnostics Limited
₹1,433.00
arrow_downward
-3.12%(-46.20) 1D
Oct 9, 3:30:00 PM GMT+5:30 · INR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for MOLBIO...
Open
₹1,481.20
High
₹1,488.90
Low
₹1,427.10
Mkt. cap
165.89B
Avg. vol.
3.23M
Volume
779.88K
P/E ratio
96.99
52-wk high
₹1,686.80
52-wk low
₹926.35
EPS
₹14.77
No. of employees
1K
Open
₹1,481.20
High
₹1,488.90
Low
₹1,427.10
Mkt. cap
165.89B
Avg. vol.
3.23M
Volume
779.88K
P/E ratio
96.99
52-wk high
₹1,686.80
52-wk low
₹926.35
EPS
₹14.77
No. of employees
1K
News stories
From web sources and news partners
Stock Traders Daily
·
4 hours ago
(CVCO) Risk Channels and Responsive Allocation
Yahoo Finance
·
11 hours ago
A COVID Vaccine Stock on the S&P 500 Is Up 600% This Year
MyStateline
·
1 day ago
Wall Street finishes its record-setting week with gains
MarketWatch
·
23 hours ago
S&P 500 at 10,000 or bust: New ETF offers investors all-or-nothing bet on the index
Profile
Molbio Diagnostics Limited is an Indian medical diagnostics company headquartered in Verna, Goa, that develops molecular diagnostic technologies. Founded in 2000, the company developed the Truenat platform, a portable real-time PCR system used to diagnose infectious diseases including tuberculosis, HIV, and hepatitis.
The Truenat platform is recognized by the World Health Organization for the initial detection of tuberculosis and rifampicin resistance. Following clinical studies, including research published in The Lancet, the technology has been adopted by national health programs in over 85 countries.
In 2025, Molbio was awarded the Kochon Prize by the Stop TB Partnership, the world's largest award for tuberculosis. Wikipedia
About Molbio Diagnostics Limited